Eurolife Healthcare Acquires Teva's IV Drug Manufacturing Facility in Hungary

On July 22, 2019, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that Indian pharmaceutical company Eurolife Healthcare (Eurolife) announced the acquisition of an intravenous drug manufacturing plant owned by Israel’s Teva Pharmaceutical Industries Ltd. (Teva). No financial terms of the acquisition were disclosed.

It is reported that the acquired factory is located in Hungary, Europe, and currently has a monthly production capacity of 2.1 million bags of intravenous infusion fluids. Sandeep Toshniwal, CEO of Eurolife, stated, “Over the next three years, Eurolife will invest €50 million to expand this facility.” Following the acquisition, Eurolife will expand its exports of intravenous medications to markets in Europe and the United States.

Teva Pharmaceutical Industries Ltd., founded in 1901 and headquartered in Israel, is one of the top 20 pharmaceutical companies globally and the world’s largest manufacturer of generic drugs. Listed on the New York Stock Exchange since 1982, the company focuses on the development, production, and sales of high-quality generic and branded medicines, providing healthcare security to millions of patients worldwide. Teva offers more than 3,500 marketed products, operates 70 manufacturing facilities, and produces approximately 120 billion tablets annually. With a global workforce of 43,000 employees, the company exports pharmaceuticals to 60 countries.

Teva’s R&D pipeline primarily targets diseases in the central nervous system and respiratory systems, including migraine, neurodegenerative diseases, and bronchitis. Statistics show that approximately one in nine prescription drugs in the United States are manufactured by Teva.

Teva is a leading global supplier of active pharmaceutical ingredients (APIs). Its independent business unit, Teva Active Pharmaceutical Ingredients (TAPI), operates 18 advanced manufacturing facilities, providing more than 370 high-quality APIs to nearly 1,000 customers in over 100 countries. More than 5,000 highly trained TAPI professionals are dedicated to extracting natural active pharmaceutical ingredients to ensure a sustainable supply of APIs.

In addition, Teva is also focused on the healthcare industry. The company has partnered with the Arnhold Institute, one of the largest medical institutions in the United States, to provide patients with new approaches for the prevention and treatment of chronic diseases such as cardiovascular disease, diabetes, obesity, and pulmonary disorders. Meanwhile, Teva aims to collaborate with numerous healthcare enterprises to jointly establish a new healthcare system tailored for the 21st century.

Eurolife, established in 2001 and headquartered in Mumbai, India, is a specialized pharmaceutical company. The company primarily manufactures and distributes intravenous (IV) drugs, sterile water for injection, healthcare products, anti-infective agents, and nutritional supplements, providing patients with high-quality, cost-effective products. As India’s largest producer of intravenous drugs, Eurolife operates multiple pharmaceutical manufacturing facilities across various regions of India, supplying medications to 12,000 hospitals and nursing homes. In 2016, Eurolife acquired the flexible fluid systems (FFS) infusion therapy business from Baxter India, a subsidiary of the US biotechnology company Baxter International, thereby enhancing its competitiveness in the global pharmaceutical market.

Eurolife’s pharmaceutical products have been certified under the Good Manufacturing Practice (GMP) standards. The company is currently expanding its manufacturing facilities to grow its presence in the Indian market and to export medicines to multiple countries, including Ukraine, Kenya, the Philippines, Nepal, and Kazakhstan.

(Compiled by Xu Xiaoxue)